Parkinson's disease Archives - Medical Design Sourcing

AbbVie launches Produodopa in the EU to treat Parkinson’s

AbbVie (NYSE: ABBV) recently announced the launch of its Parkinson’s disease drug Produodopa (foslevodopa/foscarbidopa) in the European Union.

Produodopa is for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement). It’s indicated for use when combinations of Parkinson’s medicinal products have not given satisfactory results.

North Chicago, Illinois–based Abbvie described Produodopa as the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations. The continuous delivery of Produodopa provides levodopa 24 hours a day. According to AbbVie, this could help patients by extending the period when symptoms are well-controlled, often referred to as “On” time.

“People living with Parkinson’s disease experience daily challenges and uncertainty, especially as th…

Researchers develop at-home device to track Parkinson’s progression

An at-home monitoring system could help monitor Parkinson’s progression and response to medication. [Image by N.Fuller/SayoStudio]

Researchers at MIT and the University of Rochester Medical Center have developed a device to monitor a Parkinson’s patient at home.

Collecting data at home could help provide a less subjective measurement than evaluations at the doctor’s office, which can be affected by outside factors. The technology could also help pharmaceutical and biotech companies developing new therapies for Parkinson’s, which is the world’s fastest-growing neurological disease.

In a one-year study with 50 patients, machine learning algorithms analyzed the data to help clinicians track Parkinson’s progression and medication response more effectively than periodic evaluations in a medical facility, MIT said in a news release. The study fund that gait speed declined ne…

Bayer moves forward with cell and gene therapies for Parkinson’s disease

Bayer announced today that its BlueRock Therapeutics subsidiary successfully administered the first dose of its Parkinson’s disease therapies.

Berlin-based Bayer said in a news release that BlueRock successfully administered the dose of its investigational pluripotent stem cell-derived dopaminergic neruons, called DA01, to a Parkinson’s disease patient in an open-label Phase 1 clinical safety and tolerability study.

Additionally, Bayer said its wholly-owned, clinical-stage adeno-associated virus (AAV) gene therapy company, Asklepios BioPharmaceutical (AskBio), is currently recruiting and evaluating patients in an ongoing Phase 1b clinical study to assess the safety and preliminary efficacy of a parallel gene therapy program for Parkinson’s disease.

BlueRock will enroll 10 patients across the U.S. and Canada. Those enrolled will undergo surgical transplantation of the dopamine-producing cells into the putamen deep brain structure, with a…

What is needed to develop disease-modifying therapies for Parkinson’s and Alzheimer’s

Photo by Edward Jenner from Pexels

Developing disease-modifying therapies for neurodegenerative diseases remains a pressing need.

The incidence of neurodegenerative disease is ramping up in the U.S. and elsewhere as much of the global population ages. One out of three seniors dies with Alzheimer’s disease or another form of dementia, according to the Alzheimer’s Association.

Parkinson’s disease is also becoming more widespread. Between 2015 and 2040, the number of people with Parkinson’s could nearly triple, rising from 6.3 to 17.5 million.

But developing drugs that can slow or stop the progression of such diseases poses a significant challenge for drug developers. Eli Lilly’s donanemab, for instance, showed promise earlier this year in treating Alzheimer’s in a Phase 2 study summarized in NEJM.

Another Alheimer’s candidate, aducanumab from Biogen, has also shown promise, although late l…